Dendritic Cell Vaccination in Medullary Thyroid Carcinoma

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 2944-2953

  Stift, Anton ^a   Sachet, Monika ^a   Yagubian, Rubina ^a   Bittermann, Clemens ^a   Dubsky, Peter ^b   Brostjan, Christine ^a   Pfragner, Roswitha ^c   Niederle, Bruno ^a   Jakesz, Raimund ^a   Gnant, Michael ^a   Friedl, Josef ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE ANTIBODY; INTERLEUKIN 4; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DENDRITIC CELL VACCINATION; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INGUINAL LYMPH NODE; MALE; PRIORITY JOURNAL; PROGNOSIS; PULSATILE DRUG RELEASE; SKIN INDURATION; THYROID MEDULLARY CARCINOMA; TUMOR CELL DESTRUCTION; VACCINATION;

ADULT; AGED; CALCITONIN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 2442474103     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0698     Document Type: Article

References (36)

1. Gimm O, Dralle H. C-cell cancer-prevention and treatment. Langenbeck's Arch Surg 1999;384:16-23.
2. Vitale G, Canaglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer (Phila) 2001;91:1797-808.
3. Orlandi F, Caraci P, Mussa A, et al. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 2001;8:135-47.
4. Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 1998;9:695-701.
5. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer (Phila) 2000;88: 1139-48.
6. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid 1995;5:407-24.
7. Juweid ME, Hajjar G, Swayne LC, et al. Phase I/II trial of (131)I-MN-14F(ab)2 anticarcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer (Phila) 1999;85:1828-42.
8. Minemura K, Takeda T, Minemura K, et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology 2000;141:1814-22.
9. Soler MN, Milhaud G, Lekmine F, et al. Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol Immunother 1999;48:91-9.
10. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 1997;226: 1-5.
11. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature (Lond) 1998;392:245-52.
12. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
13. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46: 82-7.
14. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
15. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137:1142-62.
16. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
17. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a Phase H prostate cancer vaccine trial. Prostate 1999;40:125-9.
18. Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369-76.
19. Chang AE, Redman BG, Whitfield JR, et al. A Phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-32.
20. Zhen S, Dannull J, Heiser A, et al. Immunologcial and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-33.
21. Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Investig 2003;21:341-9.
22. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88.
23. Schott M, Seissler J, Lettmann M, et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001;86:4965-9.
24. Bachleitner-Hofmann T, Stift A, Friedl J, et al. Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 2002;87:1098-104.
25. Kern F, Surel IP, Brock C, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998;8:975-78.
26. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003;21:135-42.
27. Brostjan C, Bayer A, Zommer A, et al. Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer (Phila) 2003;98:2291-301.
28. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
29. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996;93:2588-92.
30. Chen B, Shi Y, Smith JD, et al. The role of tumor necrosis factor a in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 1998;91:4652-61.
31. Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
32. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193: 233-8.
33. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 2002;99: 931-6.
34. Thumann P, Moc I, Humrich J, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003;277: 1-16.
35. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-9.
36. + T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.